The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis

Dupilumab demonstrated efficacy with an acceptable safety profile in two randomized, double‐blind, placebo‐controlled, parallel‐group, phase III trials in adolescents (12–17 years; LIBERTY AD ADOL) and children (6–11 years; LIBERTY AD PEDS) with atopic dermatitis (AD) treated for 16 weeks. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamal, Mohamed A., Kovalenko, Pavel, Kosloski, Matthew P., Srinivasan, Kamal, Zhang, Yi, Rajadhyaksha, Manoj, Lai, Ching‐Ha, Kanamaluru, Vanaja, Xu, Christine, Sun, Xian, Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Shumel, Brad, Bansal, Ashish, Al‐Huniti, Nidal, Davis, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290854/
https://www.ncbi.nlm.nih.gov/pubmed/34270797
http://dx.doi.org/10.1002/cpt.2366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290854/
https://www.ncbi.nlm.nih.gov/pubmed/34270797
http://dx.doi.org/10.1002/cpt.2366

Ejemplares similares